CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference

17 يونيو 2021 09:00:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics to Participate in BIO Digital 2021 Conference

10 يونيو 2021 09:15:00 بحسب Nasdaq GlobeNewswire

Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

18 مايو 2021 08:30:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

13 مايو 2021 16:05:00 بحسب Nasdaq GlobeNewswire

Capricor to Present at the American Society of Gene and Cell Therapy’s 24th Annual Meeting

12 مايو 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13

06 مايو 2021 08:30:02 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio

29 أبريل 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

11 مارس 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform

09 مارس 2021 09:15:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11

04 مارس 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines

01 فبراير 2021 09:15:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes

19 يناير 2021 09:15:00 بحسب Nasdaq GlobeNewswire

Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

12 يناير 2021 09:05:00 بحسب Nasdaq GlobeNewswire